Catalyst
Slingshot members are tracking this event:
Fibrocell Announces Initiation of Patient Recruitment in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FCSC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 13, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fcx-007, Recessive Dystrophic Epidermolysis Bullosa, Rdeb, Fcx-013
